Cas no 117976-90-6 (Rabeprazole sodium)

Rabeprazole sodium is a proton pump inhibitor (PPI) used to suppress gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme in gastric parietal cells. It is commonly prescribed for treating gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sodium salt form enhances solubility and bioavailability, ensuring rapid onset of action. Rabeprazole sodium exhibits high acid stability and selective accumulation in acidic compartments, improving therapeutic efficacy. Its metabolic pathway involves minimal cytochrome P450 interaction, reducing potential drug-drug interactions compared to other PPIs. The compound is typically administered in delayed-release formulations to protect it from gastric degradation. Clinical studies demonstrate consistent acid suppression and favorable tolerability profiles.

Rabeprazole sodium structure

Product Name:Rabeprazole sodium

CAS No:117976-90-6

MF:C₁₈H₂₀N₃NaO₃S

MW:381.424473762512

MDL:MFCD26405704

CID:63325

PubChem ID:253660182

Update Time:2026-01-22

Rabeprazole sodium Chemical and Physical Properties

Names and Identifiers

- Rebeprazole sodium
- 2-[[[4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE, SODIUM SALT
- 2-[[[4-(3-METHOXYPROPOXY)-3-METHYLPYRIDIN-2-YL]METHYL]SULFINY]-1H-BENZIMIDAZOLE SODIUM SALT
- sodium 2-[[4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl]methylsulfinyl]benzoimidazole
- SODIUM RABEPRAZOLE
- PARIET
- RABEPRAZOLE SODIUM
- RABEPRAZOLE, SODIUM SALT
- LY307640 sodium
- Rabeprazole (sodium salt)
- Rabeprazole Sodium S
- 2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole,Pariprazole
- sodium,2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
- 2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
- Pariprazole
- Parie
- RABEPRAZOL SODIUM
- Rabeprazole SoduiM
- Dexrabeprazole SodiuM
- Rabeprazole SodiuM USP
- Rabeprazole sodium salt
- Aciphex Sodium
- LY 307640 sodium
- Habeprazole Sodium
- Rabeprazole sodium [USAN]
- E 3810
- (S)-Rabeprazole Sodium Salt
- DSSTox_RID_80118
- DSSTox_CID_24205
- 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole sodium salt
- C18H20N3NaO3S
- DSSTox_GSID_44205
- 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
- LY307640
- HMS2093H10
- AKOS015962116
- D00724
- RABEPRAZOLE SODIUM (USP-RS)
- HMS3373B05
- RABEPRAZOLE SODIUM (MART.)
- Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
- rabeprazole sodium delayed-release
- Aciphex
- RABEPRAZOLE SODIUM [USP-RS]
- Tox21_302317
- RABEPRAZOLE SODIUM [MART.]
- RABEPRAZOLE SODIUM (EP MONOGRAPH)
- Rabeprazole (sodium)
- RABEPRAZOLE SODIUM [EP MONOGRAPH]
- pariete
- F17418
- CCG-213574
- s4665
- RABEPRAZOLE NA [VANDF]
- Q27108142
- BR167318
- 1216494-11-9
- EX-A176
- sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
- Q-201655
- sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
- 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1)
- MLS006010621
- (R)-Rabeprazole-d3 Sodium Salt
- HMS2231E04
- Rabeprazole sodium (JP17/USP)
- DTXCID1024205
- Idiazole
- J-010726
- NSC-759270
- NCGC00159518-02
- AKOS015895734
- Sodium (S)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
- NSC 759270
- E3810
- BCP06639
- RABEPRAZOLE SODIUM [ORANGE BOOK]
- BDBM50247881
- RABEPRAZOLE SODIUM [USP MONOGRAPH]
- SMR000550493
- CHEBI:8769
- SR-01000799133-2
- Sodium, Rabeprazole
- DTXSID3044205
- Rebeprazole sodium;
- Rabeprazole na
- [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
- FT-0631090
- 117976-90-6
- Rabeprazole SodiumDR
- Pariet (TN)
- R0115
- Rabeprazole sodium, >=98% (HPLC)
- Tox21_111736
- RABEPRAZOLE SODIUM SALT [MI]
- Aciphex Sprinkle
- (Former JAN: Sodium Rabeprazole)
- Aciphex (TN)
- LY-307640 SODIUM
- Pepcia
- SR-01000799133
- UNII-3L36P16U4R
- KRCQSTCYZUOBHN-UHFFFAOYSA-N
- MFCD02092688
- Tox21_111736_1
- NCGC00159518-05
- MLS001165734
- AC-715
- 171440-19-0
- Rabeprazole sodium- Bio-X
- RABERPRAZOLE SODIUM D/R
- AM81231
- Dexrabeprazolesodium
- C07865
- 3L36P16U4R
- CCG-268423
- RABEPRAZOLE SODIUM [JAN]
- AS-13338
- RABEPRAZOLE SODIUM [WHO-DD]
- NCGC00255838-01
- Monosodium (RS)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazolide
- sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
- CHEMBL1200930
- Rabicip
- CAS-117976-90-6
- RABEPRAZOLE SODIUM (USP MONOGRAPH)
- LY-307640
- FT-0689461
- 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole sodium salt
- sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
- Pariprazole sodium
- E-3810 SODIUM
- AKOS025310160
- sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzimidazol-1-ide
- Rablet
- SCHEMBL140494
- HY-B0656A
- Rabeprazole sodium
- MDL： MFCD26405704
- Inchi： 1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
- InChI Key： KRCQSTCYZUOBHN-UHFFFAOYSA-N
- SMILES： S(C1=NC2C=CC=CC=2[N-]1)(CC1C(C)=C(C=CN=1)OCCCOC)=O.[Na+]

Computed Properties

Exact Mass: 381.11200
Monoisotopic Mass: 381.112307
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 0
Hydrogen Bond Acceptor Count: 7
Heavy Atom Count: 26
Rotatable Bond Count: 8
Complexity: 446
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 81.5

Experimental Properties

Color/Form: Powder
Density: 0.45~0.55 g/ml
Melting Point: 150°C(lit.)
Boiling Point: 603.9°C at 760 mmHg
Flash Point: No data available
Solubility: H2O: soluble10mg/mL (clear solution)
PSA: 93.41000
LogP: 3.48420
Merck: 8089
Vapor Pressure: No data available

Rabeprazole sodium Security Information

Signal Word：Warning
Hazard Statement： H302
Warning Statement： P280-P305+P351+P338
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：3
Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Rabeprazole sodium Customs Data

HS CODE：2933399090
Customs Data：

China Customs Code:
2933399090

Overview:

2933399090. Other compounds with non fused pyridine rings in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

Summary:

2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Rabeprazole sodium Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd.	BBP80442-5mg	Rebeprazole sodium	117976-90-6	98.0%	5mg	￥100	2021-05-07
MedChemExpress	HY-B0656A-10mM*1mLinDMSO	Rabeprazole sodium	117976-90-6	99.67%	10mM*1mLinDMSO	￥550	2023-07-26
MedChemExpress	HY-B0656A-10mg	Rabeprazole sodium	117976-90-6	99.67%	10mg	￥500	2024-05-24
MedChemExpress	HY-B0656A-50mg	Rabeprazole sodium	117976-90-6	99.67%	50mg	￥921	2024-05-24
S e l l e c k ZHONG GUO	S4665-20mg	Rabeprazole sodium	117976-90-6	97%	20mg	￥794.91	2023-09-15
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	R0115-1G	Rabeprazole Sodium Salt	117976-90-6	>98.0%(HPLC)	1g	￥390.00	2024-04-18
DC Chemicals	DC9103-1 g	Rebeprazole sodium	117976-90-6	>98%	1g	$300.0	2022-02-28
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	1598019-250MG	Rabeprazole sodium	117976-90-6		250mg	￥5458.59	2025-01-11
SHANG HAI TAO SHU Biotechnology Co., Ltd.	T1651-5 mg	Rebeprazole sodium	117976-90-6	99.36%	5mg	￥236.00	2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.	T1651-10 mg	Rebeprazole sodium	117976-90-6	99.36%	10mg	￥425.00	2022-04-26

Rabeprazole sodium Production Method

Rabeprazole sodium Suppliers

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:117976-90-6)Rebeprazole sodium

Order Number:sfd5731

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:34

Price ($):discuss personally

Email:[email protected]

Product Official Link

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:117976-90-6)Rabeprazole sodium

Order Number:A803857

Stock Status:in Stock

Quantity:5g

Purity:99%

Pricing Information Last Updated:Friday, 30 August 2024 04:41

Price ($):235.0

Email:[email protected]

Product Official Link

Rabeprazole sodium Spectrogram

13C NMR

1H NMR

300 MHz

DMSO

Rabeprazole sodium Related Literature

1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?

Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?

Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
3. Excited-state proton-coupled electron transfer within ion pairs?

Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?

Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.

LarsBanko,AlfredLudwig

Related Categories

Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Additional information on Rabeprazole sodium

Rabeprazole Sodium: A Comprehensive Overview

Rabeprazole sodium, with the CAS number 117976-90-6, is a widely recognized proton pump inhibitor (PPI) that has revolutionized the treatment of various gastrointestinal disorders. As a key player in the pharmaceutical industry, rabeprazole sodium is primarily used to manage conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Its ability to effectively inhibit gastric acid secretion has made it a cornerstone in modern gastroenterology.

Rabeprazole sodium operates by targeting the hydrogen potassium ATPase enzyme, commonly referred to as the proton pump, in the parietal cells of the stomach. This inhibition leads to a significant reduction in acid production, thereby providing relief from symptoms associated with excessive acid secretion. The drug's mechanism of action is highly selective, ensuring minimal impact on other cellular functions and reducing the risk of adverse effects.

Recent studies have highlighted the role of rabeprazole sodium in not only treating acid-related disorders but also in preventing complications such as Barrett's esophagus and esophageal adenocarcinoma. These findings underscore its importance in both therapeutic and preventive healthcare strategies. Moreover, advancements in drug delivery systems have enhanced the bioavailability of rabeprazole sodium, making it more effective and convenient for patients.

The pharmacokinetics of rabeprazole sodium are well-documented, with rapid absorption following oral administration. The drug undergoes extensive first-pass metabolism in the liver, where it is converted into its active metabolites. This metabolic pathway ensures that rabeprazole sodium achieves optimal concentrations at the target site while minimizing systemic exposure. Such characteristics contribute to its favorable safety profile and make it suitable for long-term use.

One of the most significant developments in recent years is the exploration of rabeprazole sodium in combination therapies. Researchers have found that combining rabeprazole sodium with other medications can enhance its efficacy in treating complex gastrointestinal conditions. For instance, its use alongside antibiotics has proven beneficial in eradicating Helicobacter pylori infections, which are a major cause of peptic ulcers.

Another area of growing interest is the investigation into the potential off-label uses of rabeprazole sodium. Emerging evidence suggests that it may play a role in managing extragastric conditions such as respiratory diseases linked to acid reflux. This broadens its therapeutic applications and positions it as a versatile medication in clinical practice.

Despite its numerous benefits, it is crucial to consider the safety profile of rabeprazole sodium. While generally well-tolerated, long-term use has been associated with rare but serious side effects such as hypomagnesemia and bone fractures. Therefore, careful monitoring and patient education are essential to maximize its benefits while minimizing risks.

In conclusion, rabeprazole sodium, with its unique mechanism of action and extensive clinical applications, remains a pivotal drug in gastroenterology. Its continued evolution through research and development ensures that it remains at the forefront of treating acid-related disorders. As new insights emerge, rabeprazole sodium will undoubtedly continue to play a vital role in improving patient outcomes worldwide.

117976-90-6 (Rabeprazole sodium) Related Products

Recommended suppliers